57 related articles for article (PubMed ID: 7716673)
21. Long-term event-free survivors after high-dose therapy and autologous stem-cell transplantation for low-grade follicular lymphoma.
Andreadis C; Schuster SJ; Chong EA; Svoboda J; Luger SM; Porter DL; Tsai DE; Nasta SD; Elstrom RL; Goldstein SC; Downs LH; Mangan PA; Cunningham KA; Hummel KA; Gimotty PA; Siegel DL; Glatstein E; Stadtmauer EA
Bone Marrow Transplant; 2005 Dec; 36(11):955-61. PubMed ID: 16205727
[TBL] [Abstract][Full Text] [Related]
22. Long-term follow-up of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy.
Querfeld C; Rosen ST; Kuzel TM; Kirby KA; Roenigk HH; Prinz BM; Guitart J
Arch Dermatol; 2005 Mar; 141(3):305-11. PubMed ID: 15781671
[TBL] [Abstract][Full Text] [Related]
23. Treatment outcome and prognostic factors for relapse after high-dose chemotherapy and peripheral blood stem cell rescue for patients with poor risk high grade non-Hodgkin's lymphoma.
Lee SM; Ryder WD; Clemons MJ; Morgenstern GR; Chang J; Scarffe JH; Radford JA
Bone Marrow Transplant; 1999 Aug; 24(3):271-7. PubMed ID: 10455365
[TBL] [Abstract][Full Text] [Related]
24. Impact of involved field radiotherapy in partial response after doxorubicin-based chemotherapy for advanced aggressive non-Hodgkin's lymphoma.
Moser EC; Kluin-Nelemans HC; Carde P; Meerwaldt JH; Tirelli U; Aleman BM; Baars J; Thomas J; van Glabbeke M; Noordijk EM
Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):1168-77. PubMed ID: 16887289
[TBL] [Abstract][Full Text] [Related]
25. Long-term follow-up of allogeneic bone marrow transplantation in patients with poor prognosis non-Hodgkin's lymphoma.
Bernard M; Dauriac C; Drénou B; Leberre C; Branger B; Fauchet R; Le Prisé PY; Lamy T
Bone Marrow Transplant; 1999 Feb; 23(4):329-33. PubMed ID: 10100576
[TBL] [Abstract][Full Text] [Related]
26. [Treatment option and outcome for patients with primary non-Hodgkin's lymphoma of the nasal cavity].
Yao B; Li YX; Song YW; Jin J; Liu YP; Wang WH; Wang SL; Sun YT; Yu ZH; Liu XF
Zhonghua Zhong Liu Za Zhi; 2006 Jan; 28(1):58-61. PubMed ID: 16737624
[TBL] [Abstract][Full Text] [Related]
27. Durability of remission after ABMT for NHL: the importance of the 2-year evaluation point.
Bolwell B; Goormastic M; Andresen S
Bone Marrow Transplant; 1997 Mar; 19(5):443-8. PubMed ID: 9052909
[TBL] [Abstract][Full Text] [Related]
28. Primary intestinal lymphoma: clinical and therapeutic features of 32 patients.
Zinzani PL; Magagnoli M; Pagliani G; Bendandi M; Gherlinzoni F; Merla E; Salvucci M; Tura S
Haematologica; 1997; 82(3):305-8. PubMed ID: 9234576
[TBL] [Abstract][Full Text] [Related]
29. Stage I and II follicular non-Hodgkin's lymphoma: long-term follow-up of no initial therapy.
Advani R; Rosenberg SA; Horning SJ
J Clin Oncol; 2004 Apr; 22(8):1454-9. PubMed ID: 15024027
[TBL] [Abstract][Full Text] [Related]
30. Clinical significance of histologic (Kiel) classification combined with immunologic definition of malignant lymphoma.
Porwit-Ksiazek A; Mioduszewska O
Neoplasma; 1983; 30(2):173-80. PubMed ID: 6601777
[TBL] [Abstract][Full Text] [Related]
31. Low-grade lymphoma: clinical and prognostic studies in a series of 143 patients from a single institution.
Lopez-Guillermo A; Montserrat E; Bosch F; Escoda L; Terol MJ; Marin P; Reverter JC; Blade J; Cervantes F; Sierra J
Leuk Lymphoma; 1994 Sep; 15(1-2):159-65. PubMed ID: 7858494
[TBL] [Abstract][Full Text] [Related]
32. [The global survival rate calculated by Kaplan-Meier method in children with malignant lymphomas].
Rugină A; Miron I; Moraru D; Tansanu I; Georgescu D; Mihăilă D
Rev Med Chir Soc Med Nat Iasi; 2006; 110(3):555-8. PubMed ID: 17571544
[TBL] [Abstract][Full Text] [Related]
33. Tisagenlecleucel in Non-Hodgkin Lymphoma: The Restricted Mean Survival Time as a Tool for Estimating Progression-Free Life Expectancy Better than the Median.
Chiumente M; Mengato D; Messori A
Acta Haematol; 2020; 143(6):598-599. PubMed ID: 32074609
[No Abstract] [Full Text] [Related]
34. Long-term follow-up after autologous hematopoietic stem cell transplantation for low-grade non-Hodgkin lymphoma.
Laudi N; Arora M; Burns LJ; Miller JS; McGlave PB; Barker JN; Ramsay NK; Orchard PJ; Macmillan ML; Weisdorf DJ
Biol Blood Marrow Transplant; 2005 Feb; 11(2):129-35. PubMed ID: 15682074
[TBL] [Abstract][Full Text] [Related]
35. [Non-Hodgkin's lymphomas. II. Analysis of the prognostic factors in a series of 307 patients].
García Zueco JC; Delgado MP; Giraldo MP; Perella M; Rubio-Félix D; Giralt M
Sangre (Barc); 1992 Oct; 37(5):337-44. PubMed ID: 1293772
[TBL] [Abstract][Full Text] [Related]
36. Allogeneic bone marrow transplantation for poor-prognosis lymphoma: response, toxicity and survival depend on disease histology.
van Besien KW; Mehra RC; Giralt SA; Kantarjian HM; Pugh WC; Khouri IF; Moon Y; Williams P; Andersson BS; Przepiorka D; McCarthy PL; Gajewski JL; Deisseroth AB; Cabanillas FF; Champlin R
Am J Med; 1996 Mar; 100(3):299-307. PubMed ID: 8629675
[TBL] [Abstract][Full Text] [Related]
37. [Post-therapeutic evolution and prognostic factors of intestinal lymphomas, Retrospective analysis of 42 cases].
Sánchez-Fayos MP; Hernández Guío C; Rivas MC; Outeiriño J; González-Campos C; Lobo F
Sangre (Barc); 1993 Dec; 38(6):455-62. PubMed ID: 8171381
[TBL] [Abstract][Full Text] [Related]
38. Primary non-Hodgkin lymphoma of the breast: The Mayo Clinic Experience.
Wong WW; Schild SE; Halyard MY; Schomberg PJ
J Surg Oncol; 2002 May; 80(1):19-25; discussion 26. PubMed ID: 11967901
[TBL] [Abstract][Full Text] [Related]
39. [Characteristics of patients with low grade malignant lymphoma and long survival].
Martínez-Francés A; Lopez-Guillermo A; Esteve J; Bosch F; Terol MJ; Montserrat E; Rozman C
Sangre (Barc); 1995 Feb; 40(1):53-7. PubMed ID: 7716673
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
